Standing pat

Investors agree that new generalist money will be needed to sustain biotech’s rally in 2H17, but the opposite has played out in the early innings.

Mixed results from key 3Q17 milestones and the continued lack of big acquisition deals have kept generalists looking elsewhere -- and this isn’t expected to change near-term...